Pyrrolidine based peptidomimetics are reported as potent and selective DPP-IV inhibitors for the treatment of T2DM. Compounds 16c and 16d showed excellent in vitro potency and selectivity towards DPP-IV and the lead compound 16c showed sustained antihyperglycemic effects, along with improved pharmacokinetic profile. (C) 2012 Elsevier Ltd. All rights reserved.
Guenther, Robert; Bordusa, Frank, Chemistry - A European Journal, 2000, vol. 6, # 3, p. 463 - 467